Trial Profile
A Phase I dose-escalating and safety study of AZD8931 in combination with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2022
Price :
$35
*
At a glance
- Drugs Sapitinib (Primary) ; Capecitabine; Oxaliplatin
- Indications Adenocarcinoma; Carcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms DEBIOC
- Sponsors AstraZeneca
- 31 May 2020 Results evaluating translational analysis impact of neoadjuvant Xelox with or without Sapitinib presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 22 Nov 2019 Results assessing the recommended phase II dose (RP2D) of AZD8931 plus chemotherapy, and subsequently assess safety/preliminary clinical activity in patients with operable oesophagogastric cancer published in the European Journal of Cancer
- 17 Aug 2018 Planned End Date changed from 29 Feb 2016 to 15 Nov 2018.